Document:

Exhibit 4.1

 

MEDYTOX SOLUTIONS, INC.

2013 INCENTIVE COMPENSATION PLAN

 

1.ESTABLISHMENT,
EFFECTIVE DATE AND TERM

 

Medytox Solutions,
Inc., a Nevada corporation, hereby establishes the Medytox Solutions, Inc. 2013 Incentive Compensation Plan. The Effective Date
of the Plan shall be the later of: (i) the date the Plan was approved by the Board, and (ii) the date the Plan was approved by
stockholders of Medytox in accordance with the laws of the State of Nevada. Unless earlier terminated pursuant to Section 14(k)
hereof, the Plan shall terminate on the tenth anniversary of the Effective Date. Capitalized terms used herein are defined in Annex
A attached hereto.

 

2.PURPOSE

 

The purpose of the
Plan is to enable Medytox to attract, retain, reward and motivate Eligible Individuals by providing them with an opportunity to
acquire or increase a proprietary interest in Medytox and to incentivize them to expend maximum effort for the growth and success
of the Company, so as to strengthen the mutuality of the interests between the Eligible Individuals and the stockholders of Medytox.

 

3.ELIGIBILITY

 

Awards may be granted
under the Plan to any Eligible Individual, as determined by the Committee from time to time, on the basis of their importance to
the business of the Company, pursuant to the terms of the Plan.

 

4.ADMINISTRATION

 

(a)Committee.
The Plan shall be administered by the Committee, which shall have the full power and authority to take all actions, and to
make all determinations not inconsistent with the specific terms and provisions of the Plan and deemed by the Committee to be necessary
or appropriate to the administration of the Plan, any Award granted or any Award Agreement entered into hereunder. The Committee
may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any Award Agreement in the manner
and to the extent it shall deem expedient to carry the Plan into effect as it may determine in its sole discretion. The decisions
by the Committee shall be final, conclusive and binding with respect to the interpretation and administration of the Plan, any
Award or any Award Agreement entered into under the Plan.

 

(b)Delegation
to Officers or Employees. The Committee may designate officers or employees of the Company to assist the Committee in
the administration of the Plan. The Committee may delegate authority to officers or employees of the Company to grant Awards and
execute Award Agreements or other documents on behalf of the Committee in connection with the administration of the Plan, subject
to whatever limitations or restrictions the Committee may impose and in accordance with applicable law.

 

    	1

    	 

    

 

(c)Designation
of Advisors. The Committee may designate professional advisors to assist the Committee in the administration of the
Plan. The Committee may employ such legal counsel, consultants, and agents as it may deem desirable for the administration of the
Plan and may rely upon any advice and any computation received from any such counsel, consultant, or agent. The Company shall pay
all expenses and costs incurred by the Committee for the engagement of any such counsel, consultant, or agent.

 

(d)Participants
Outside the U.S. In order to conform with the provisions of local laws and regulations of foreign countries which may
affect the Awards or the Participants, the Committee shall have the sole discretion to (i) modify the terms and conditions of the
Awards granted under the Plan to Eligible Individuals located outside the United States; (ii)  establish subplans with such
modifications as may be necessary or advisable under the circumstances present by local laws and regulations; and (iii) take any
action which it deems advisable to comply with or otherwise reflect any necessary governmental regulatory procedures, or to obtain
any exemptions or approvals necessary with respect to the Plan or any subplan established hereunder.

 

(e)Liability and
Indemnification. No Covered Individual shall be liable for any action or determination made in good faith with respect
to the Plan, any Award granted hereunder or any Award Agreement entered into hereunder. The Company shall, to the maximum extent
permitted by applicable law and the Articles of Incorporation and Bylaws of Medytox, indemnify and hold harmless each Covered Individual
against any cost or expense (including reasonable attorney fees reasonably acceptable to the Company) or liability (including any
amount paid in settlement of a claim with the approval of the Company), and amounts advanced to such Covered Individual necessary
to pay the foregoing at the earliest time and to the fullest extent permitted, arising out of any act or omission to act in connection
with the Plan, any Award granted hereunder or any Award Agreement entered into hereunder. Such indemnification shall be in addition
to any rights of indemnification such individuals may have under other agreements, applicable law or under the Articles of Incorporation
or Bylaws of Medytox. Notwithstanding anything else herein, this indemnification will not apply to the actions or determinations
made by a Covered Individual with regard to Awards granted to such Covered Individual under the Plan or arising out of such Covered
Individual’s own fraud or bad faith.

 

5.SHARES
OF COMMON STOCK SUBJECT TO PLAN

 

(a)Shares Available
for Awards. The Common Stock that may be issued pursuant to Awards granted under the Plan shall be treasury shares or
authorized but unissued shares of the Common Stock. The total number of shares of Common Stock that may be issued pursuant to Awards
granted under the Plan shall be 5,000,000 shares.

 

(b)Certain Limitations
on Specific Types of Awards. The granting of Awards under this Plan shall be subject to the following limitations:

 

    	2

    	 

    

 

(i)With
respect to the shares of Common Stock issuable pursuant to this Section, a maximum of 5,000,000 of such shares may be subject to
grants of Incentive Stock Options;

 

(ii)With
respect to the shares of Common Stock issuable pursuant to this Section, a maximum of 5,000,000 of such shares may be issued in
connection with Awards, other than Stock Options and Stock Appreciation Rights, that are settled in Common Stock;

 

(iii)With
respect to the shares of Common Stock issuable pursuant to this Section, a maximum of 400,000 of such shares may be subject to
grants of Options or Stock Appreciation Rights to any one Eligible Individual during any one fiscal year;

 

(iv)With
respect to the shares of Common Stock issuable pursuant to this Section, a maximum of 400,000 of such shares may be subject to
grants of Performance Shares, Restricted Stock, and Awards of Common Stock to any one Eligible Individual during any one fiscal
year; and

 

(v)The
maximum value at Grant Date of grants of Performance Units which may be granted to any one Eligible Individual during any one fiscal
year shall be $1,000,000.

 

(c)Reduction of
Shares Available for Awards. Upon the granting of an Award, the number of shares of Common Stock available for issuance
under this Section for the granting of further Awards shall be reduced as follows:

 

(i)In connection
with the granting of an Option or Stock Appreciation Right, the number of shares of Common Stock shall be reduced by the number
of shares of Common Stock subject to the Option or Stock Appreciation Right;

 

(ii)In
connection with the granting of an Award that is settled in Common Stock, other than the granting of an Option or Stock Appreciation
Right, the number of shares of Common Stock shall be reduced by the number of shares of Common Stock subject to the Award; and

 

(iii)Awards
settled in cash or property other than Common Stock shall not count against the total number of shares of Common Stock available
to be granted pursuant to the Plan.

 

(d)Cancelled,
Forfeited, or Surrendered Awards. Notwithstanding anything to the contrary in this Plan, if any award under this Plan
is cancelled, forfeited or terminated for any reason prior to exercise, delivery or becoming vested in full, the shares of Common
Stock that were subject to such Award shall, to the extent cancelled, forfeited or terminated, immediately become available for
future Awards granted under this Plan; provided, however, that any shares of Common Stock subject to an Award which is cancelled,
forfeited or terminated in order to pay the exercise price of a stock option, purchase price or any taxes or tax withholdings on
an award shall not be available for future Awards granted under this Plan.

 

    	3

    	 

    

 

(e)Recapitalization.
If the outstanding shares of Common Stock are increased or decreased or changed into or exchanged for a different number or
kind of shares or other securities by reason of any recapitalization, reclassification, reorganization, stock split, reverse split,
combination of shares, exchange of shares, stock dividend or other distribution payable in capital stock of Medytox or other increase
or decrease in such shares effected without receipt of consideration by Medytox occurring after the Effective Date, an appropriate
and proportionate adjustment shall be made by the Committee to: (i) the aggregate number and kind of shares of Common Stock available
under the Plan (including, but not limited to, the limits of the number of shares of Common Stock described in Section 5(b)), (ii)
the calculation of the reduction of shares of Common Stock available under the Plan, (iii) the number and kind of shares of Common
Stock issuable pursuant to outstanding Awards granted under the Plan and/or (iv) the Exercise Price of outstanding Options or Stock
Appreciation Rights granted under the Plan. No fractional shares of Common Stock or units of other securities shall be issued pursuant
to any such adjustment under this Section 5(e), and any fractions resulting from any such adjustment shall be eliminated in each
case by rounding downward to the nearest whole share or unit. Any adjustments made under this Section 5(e) with respect to any
Incentive Stock Options must be made in accordance with Code Section 424.

 

6.OPTIONS

 

(a)Grant of Options.
Subject to the terms and conditions of the Plan, the Committee may grant to such Eligible Individuals as the Committee may
determine, Options to purchase such number of shares of Common Stock and on such terms and conditions as the Committee shall determine
in its sole and absolute discretion. Each grant of an Option shall satisfy the requirements set forth in this Section.

 

(b)Type of Options.
Each Option granted under the Plan may be designated by the Committee, in its sole discretion, as either (i) an Incentive Stock
Option, or (ii) a Non-Qualified Stock Option. Options designated as Incentive Stock Options that fail to continue to meet the requirements
of Code Section 422 shall be re-designated as Non-Qualified Stock Options automatically on the date of such failure to continue
to meet such requirements without further action by the Committee. In the absence of any designation, Options granted under the
Plan will be deemed to be Non-Qualified Stock Options.

 

(c)Exercise Price.
Subject to the limitations set forth in the Plan relating to Incentive Stock Options, the Exercise Price of an Option shall
be fixed by the Committee and stated in the respective Award Agreement, provided that the Exercise Price of the shares of Common
Stock subject to such Option may not be less than Fair Market Value of such Common Stock on the Grant Date, or if greater, the
par value of the Common Stock.

 

(d)Limitation
on Repricing. Unless such action is approved by Medytox’s stockholders in accordance with applicable law: (i)
no outstanding Option granted under the Plan may be amended to provide an Exercise Price that is lower than the then-current Exercise
Price of such outstanding Option (other than adjustments to the Exercise Price pursuant to Sections 5(e) and 11); (ii) the Committee
may not cancel any outstanding Option and grant in substitution therefore new Awards under the Plan covering the same or a different
number of shares of Common Stock and having an Exercise Price lower than the then-current Exercise Price of the cancelled Option
(other than adjustments to the Exercise Price pursuant to Sections 5(e) and 11); and (iii) the Committee may not authorize the
repurchase of an outstanding Option which has an Exercise Price that is higher than the then-current fair market value of the Common
Stock (other than adjustments to the Exercise Price pursuant to Sections 5(e) and 11).

 

    	4

    	 

    

 

(e)Limitation
on Option Period. Subject to the limitations set forth in the Plan relating to Incentive Stock Options, Options granted
under the Plan and all rights to purchase Common Stock thereunder shall terminate no later than the tenth anniversary of the Grant
Date of such Options, or on such earlier date as may be stated in the Award Agreement relating to such Option. In the case of Options
expiring prior to the tenth anniversary of the Grant Date, the Committee may in its discretion, at any time prior to the expiration
or termination of said Options, extend the term of any such Options for such additional period as it may determine, but in no event
beyond the tenth anniversary of the Grant Date thereof.

 

(f)Limitations
on Incentive Stock Options. Notwithstanding any other provisions of the Plan, the following provisions shall apply with
respect to Incentive Stock Options granted pursuant to the Plan.

 

(i)Limitation
on Grants. Incentive Stock Options may only be granted to Section 424 Employees. The aggregate Fair Market Value (determined
at the time such Incentive Stock Option is granted) of the shares of Common Stock for which any individual may have Incentive Stock
Options which first become vested and exercisable in any calendar year (under all incentive stock option plans of the Company)
shall not exceed $100,000. Options granted to such individual in excess of the $100,000 limitation, and any Options issued subsequently
which first become vested and exercisable in the same calendar year, shall automatically be treated as Non-Qualified Stock Options.

 

(ii)Minimum
Exercise Price. In no event may the Exercise Price of a share of Common Stock subject to an Incentive Stock Option be less
than 100% of the Fair Market Value of such share of Common Stock on the Grant Date.

 

(iii)Ten
Percent Stockholder. Notwithstanding any other provision of the Plan to the contrary, in the case of Incentive Stock Options
granted to a Section 424 Employee who, at the time the Option is granted, owns (after application of the rules set forth in Code
Section 424(d)) stock possessing more than ten percent of the total combined voting power of all classes of stock of Medytox, such
Incentive Stock Options (i) must have an Exercise Price per share of Common Stock that is at least 110% of the Fair Market Value
as of the Grant Date of a share of Common Stock, and (ii) must not be exercisable after the fifth anniversary of the Grant Date.

 

(g)Vesting Schedule
and Conditions. No Options may be exercised prior to the satisfaction of the conditions and vesting schedule provided
for in the Plan and in the Award Agreement relating thereto.

 

(h)Exercise.
When the conditions to the exercise of an Option have been satisfied, the Participant may exercise the Option only in accordance
with the following provisions. The Participant shall deliver to Medytox a written notice stating that the Participant is exercising
the Option and specifying the number of shares of Common Stock which are to be purchased pursuant to the Option, and such notice
shall be accompanied by payment in full of the Exercise Price of the shares for which the Option is being exercised, by one or
more of the methods provided for in the Plan. An attempt to exercise any Option granted hereunder other than as set forth in the
Plan shall be invalid and of no force and effect.

 

    	5

    	 

    

 

(i)Payment.
Payment of the Exercise Price for the shares of Common Stock purchased pursuant to the exercise of an Option shall be made by one
of the following methods:

 

(i)by cash,
certified or cashier’s check, bank draft or money order;

 

(ii)through
the delivery to Medytox of shares of Common Stock which have been previously owned by the Participant for the requisite period
necessary to avoid a charge to Medytox’s earnings for financial reporting purposes; such shares shall be valued, for purposes
of determining the extent to which the Exercise Price has been paid thereby, at their Fair Market Value on the date of exercise;
without limiting the foregoing, the Committee may require the Participant to furnish an opinion of counsel acceptable to the Committee
to the effect that such delivery would not result in Medytox incurring any liability under Section 16(b) of the Exchange Act; or

 

(iii)by
any other method which the Committee, in its sole and absolute discretion and to the extent permitted by applicable law, may permit,
including, but not limited to through a “cashless exercise sale and remittance procedure” pursuant to which the Participant
shall concurrently provide irrevocable instructions (1) to a brokerage firm approved by the Committee to effect the immediate sale
of the purchased shares and remit to Medytox, out of the sale proceeds available on the settlement date, sufficient funds to cover
the aggregate Exercise Price payable for the purchased shares plus all applicable federal, state and local income, employment,
excise, foreign and other taxes required to be withheld by the Company by reason of such exercise and (2) to Medytox to deliver
the certificates for the purchased shares directly to such brokerage firm in order to complete the sale.

 

(j)Termination
of Employment. Unless otherwise provided in an Award Agreement, upon the termination of the employment or other service
of a Participant with the Company for any reason, all of the Participant’s outstanding Options (whether vested or unvested)
shall be subject to the rules of this paragraph. Upon such termination, the Participant’s unvested Options shall expire.
Notwithstanding anything in this Plan to the contrary, the Committee may provide, in its sole and absolute discretion, that following
the termination of employment or other service of a Participant with the Company for any reason (i) any unvested Options held by
the Participant shall vest in whole or in part, at any time subsequent to such termination of employment or other service, and/or
(ii) a Participant or the Participant’s estate, devisee or heir at law (whichever is applicable), may exercise an Option,
in whole or in part, at any time subsequent to such termination of employment or other service and prior to the termination of
the Option pursuant to its terms that are unrelated to termination of service. Unless otherwise determined by the Committee, temporary
absence from employment or other service because of illness, vacation, approved leaves of absence or military service shall not
constitute a termination of employment or other service.

 

    	6

    	 

    

 

(i)Termination
for Reason Other Than Cause, Disability or Death. If a Participant’s termination of employment or other service is for
any reason other than death, Disability, Cause or a voluntary termination within ninety (90) days after occurrence of an event
which would be grounds for termination of employment or other service by the Company for Cause, any Option held by such Participant
may be exercised, to the extent exercisable at termination, by the Participant at any time within a period not to exceed ninety
(90) days from the date of such termination, but in no event after the termination of the Option pursuant to its terms that are
unrelated to termination of service.

 

(ii)Disability.
If a Participant’s termination of employment or other service with the Company is by reason of a Disability of such Participant,
any Option held by such Participant may be exercised, to the extent exercisable at termination, by the Participant at any time
within a period not to exceed one (1) year after such termination, but in no event after the termination of the Option pursuant
to its terms that are unrelated to termination of service; provided, however, that if the Participant dies within such period,
any vested Option held by such Participant upon death shall be exercisable by the Participant’s estate, devisee or heir at
law (whichever is applicable) for a period not to exceed one (1) year after the Participant’s death, but in no event after
the termination of the Option pursuant to its terms that are unrelated to termination of service.

 

(iii)Death.
If a Participant dies while in the employment or other service of the Company, any Option held by such Participant may be exercised,
to the extent exercisable at termination, by the Participant’s estate or the devisee named in the Participant’s valid
last will and testament or the Participant’s heir at law who inherits the Option, at any time within a period not to exceed
one (1) year after the date of such Participant’s death, but in no event after the termination of the Option pursuant to
its terms that are unrelated to termination of service.

 

(iv)Termination
for Cause. In the event the termination is for Cause or is a voluntary termination within ninety (90) days after occurrence
of an event which would be grounds for termination of employment or other service by the Company for Cause (without regard to any
notice or cure period requirement), any Option held by the Participant at the time of such termination shall be deemed to have
terminated and expired upon the date of such termination.

 

7.STOCK
APPRECIATION RIGHTS

 

(a)Grant of Stock
Appreciation Rights. Subject to the terms and conditions of the Plan, the Committee may grant to such Eligible Individuals
as the Committee may determine, Stock Appreciation Rights, in such amounts and on such terms and conditions as the Committee shall
determine in its sole and absolute discretion. Each grant of a Stock Appreciation Right shall satisfy the requirements as set forth
in this Section.

 

(b)Terms and Conditions
of Stock Appreciation Rights. Unless otherwise provided in an Award Agreement, the terms and conditions (including,
without limitation, the limitations on the Exercise Price, exercise period, repricing and termination) of the Stock Appreciation
Right shall be substantially identical (to the extent possible taking into account the differences related to the character of
the Stock Appreciation Right) to the terms and conditions that would have been applicable under Section 6 above were the grant
of the Stock Appreciation Rights a grant of an Option.

 

    	7

    	 

    

 

(c)Exercise of
Stock Appreciation Rights. Stock Appreciation Rights shall be exercised by a Participant only by written notice delivered
to Medytox, specifying the number of shares of Common Stock with respect to which the Stock Appreciation Right is being exercised.

 

(d)Payment of
Stock Appreciation Right. Unless otherwise provided in an Award Agreement, upon exercise of a Stock Appreciation Right,
the Participant or Participant’s estate, devisee or heir at law (whichever is applicable) shall be entitled to receive payment,
in cash, in shares of Common Stock, or in a combination thereof, as determined by the Committee in its sole and absolute discretion.
The amount of such payment shall be determined by multiplying the excess, if any, of the Fair Market Value of a share of Common
Stock on the date of exercise over the Fair Market Value of a share of Common Stock on the Grant Date, by the number of shares
of Common Stock with respect to which the Stock Appreciation Rights are then being exercised. Notwithstanding the foregoing, the
Committee may limit in any manner the amount payable with respect to a Stock Appreciation Right by including such limitation in
the Award Agreement.

 

8.RESTRICTED
STOCK

 

(a)Grant of Restricted
Stock. Subject to the terms and conditions of the Plan, the Committee may grant to such Eligible Individuals as the
Committee may determine, Restricted Stock, in such amounts and on such terms and conditions as the Committee shall determine in
its sole and absolute discretion. Each grant of Restricted Stock shall satisfy the requirements as set forth in this Section.

 

(b)Restrictions.
The Committee shall impose such restrictions on any Restricted Stock granted pursuant to the Plan as it may deem advisable
including, without limitation, time-based vesting restrictions or the attainment of Performance Goals. The determination with respect
to achievement of Performance Goals shall be made pursuant to Section 9 hereof.

 

(c)Certificates
and Certificate Legend. With respect to a grant of Restricted Stock, the Company may issue a certificate evidencing
such Restricted Stock to the Participant or issue and hold such shares of Restricted Stock for the benefit of the Participant until
the applicable restrictions expire. The Company may legend the certificate representing Restricted Stock to give appropriate notice
of such restrictions. In addition to any such legends, each certificate representing shares of Restricted Stock granted pursuant
to the Plan shall bear the following legend:

 

“Shares of stock represented
by this certificate are subject to certain terms, conditions, and restrictions on transfer as set forth in the Medytox Solutions,
Inc. 2013 Incentive Compensation Plan (the “Plan”), and in an agreement entered into by and between the registered
owner of such shares and Medytox Solutions, Inc. (the “Company”), dated ___, 20__ (the “Award Agreement”).
A copy of the Plan and the Award Agreement may be obtained from the Secretary of the Company.”

 

    	8

    	 

    

 

(d)Removal of
Restrictions. Except as otherwise provided in the Plan, shares of Restricted Stock shall become freely transferable
by the Participant upon the lapse of the applicable restrictions. Once the shares of Restricted Stock are released from the restrictions,
the Participant shall be entitled to have the legend required by paragraph (c) above removed from the share certificate evidencing
such Restricted Stock and the Company shall pay or distribute to the Participant all dividends and distributions held in escrow
by the Company with respect to such Restricted Stock, if any.

 

(e)Stockholder
Rights. Unless otherwise provided in an Award Agreement, until the expiration of all applicable restrictions, (i) the
Restricted Stock shall be treated as outstanding, (ii) the Participant holding shares of Restricted Stock may exercise full voting
rights with respect to such shares, and (iii) the Participant holding shares of Restricted Stock shall be entitled to receive all
dividends and other distributions paid with respect to such shares while they are so held. If any such dividends or distributions
are paid in shares of Common Stock, such shares shall be subject to the same restrictions on transferability and forfeitability
as the shares of Restricted Stock with respect to which they were paid. Notwithstanding anything to the contrary, at the discretion
of the Committee, all such dividends and distributions may be held in escrow by the Company (subject to the same restrictions on
forfeitability) until all restrictions on the respective Restricted Stock have lapsed.

 

(f)Termination
of Service. Unless otherwise provided in an Award Agreement, if a Participant’s employment or other service with
the Company terminates for any reason, all unvested shares of Restricted Stock held by the Participant and any dividends or distributions
held in escrow by the Company with respect to such Restricted Stock shall be forfeited immediately and returned to the Company.
Notwithstanding this paragraph, to the extent applicable, all grants of Restricted Stock that vest solely upon the attainment of
Performance Goals shall be treated pursuant to the terms and conditions that would have been applicable under Section 9 as if such
grants of Restricted Stock were Awards of Performance Shares. Notwithstanding anything in this Plan to the contrary, the Committee
may provide, in its sole and absolute discretion, that following the termination of employment or other service of a Participant
with the Company for any reason, any unvested shares of Restricted Stock held by the Participant that vest solely upon a future
service requirement shall vest in whole or in part, at any time subsequent to such termination of employment or other service.

 

9.PERFORMANCE
SHARES AND PERFORMANCE UNITS

 

(a)Grant of Performance
Shares and Performance Units. Subject to the terms and conditions of the Plan, the Committee may grant to such Eligible
Individuals as the Committee may determine, Performance Shares and Performance Units, in such amounts and on such terms and conditions
as the Committee shall determine in its sole and absolute discretion. Each grant of a Performance Share or a Performance Unit shall
satisfy the requirements as set forth in this Section.

 

    	9

    	 

    

 

(b)Performance
Goals. Performance Goals will be based on one or more of the following criteria, as determined by the Committee in its
absolute and sole discretion: (i) the attainment of certain target levels of, or a specified increase in, Medytox’s enterprise
value or value creation targets; (ii) the attainment of certain target levels of, or a percentage increase in, Medytox’s
after-tax or pre-tax profits including, without limitation, that attributable to Medytox’s continuing and/or other operations;
(iii) the attainment of certain target levels of, or a specified increase relating to, Medytox’s operational cash flow or
working capital, or a component thereof; (iv) the attainment of certain target levels of, or a specified decrease relating to,
Medytox’s operational costs, or a component thereof; (v) the attainment of a certain level of reduction of, or other specified
objectives with regard to limiting the level of increase in all or a portion of bank debt or other of Medytox’s long-term
or short-term public or private debt or other similar financial obligations of Medytox, which may be calculated net of cash balances
and/or other offsets and adjustments as may be established by the Committee; (vi) the attainment of a specified percentage increase
in earnings per share or earnings per share from Medytox’s continuing operations; (vii) the attainment of certain target
levels of, or a specified percentage increase in, Medytox’s net sales, revenues, net income or earnings before income tax
or other exclusions; (viii) the attainment of certain target levels of, or a specified increase in, Medytox’s return on capital
employed or return on invested capital; (ix) the attainment of certain target levels of, or a percentage increase in, Medytox’s
after-tax or pre-tax return on stockholder equity; (x) the attainment of certain target levels in the fair market value of Medytox’s
Common Stock; (xi) the growth in the value of an investment in the Common Stock assuming the reinvestment of dividends; and/or
(xii) the attainment of certain target levels of, or a specified increase in, EBITDA (earnings before income tax, depreciation
and amortization). In addition, Performance Goals may be based upon the attainment by a subsidiary, division or other operational
unit of Medytox of specified levels of performance under one or more of the measures described above. Further, the Performance
Goals may be based upon the attainment by Medytox (or a subsidiary, division, facility or other operational unit of Medytox) of
specified levels of performance under one or more of the foregoing measures relative to the performance of other corporations.
To the extent permitted under Section 162(m) of the Code (including, without limitation, compliance with any requirements for stockholder
approval), the Committee may, in its sole and absolute discretion: (i) designate additional business criteria upon which the Performance
Goals may be based; (ii) modify, amend or adjust the business criteria described herein; or (iii) incorporate in the Performance
Goals provisions regarding changes in accounting methods, corporate transactions (including, without limitation, dispositions or
acquisitions) and similar events or circumstances. Performance Goals may include a threshold level of performance below which no
Award will be earned, levels of performance at which an Award will become partially earned and a level at which an Award will be
fully earned.

 

(c)Terms and Conditions
of Performance Shares and Performance Units. The applicable Award Agreement shall set forth (i) the number of Performance
Shares or the dollar value of Performance Units granted to the Participant; (ii) the Performance Period and Performance Goals with
respect to each such Award; (iii) the threshold, target and maximum shares of Common Stock or dollar values of each Performance
Share or Performance Unit and corresponding Performance Goals; and (iv) any other terms and conditions as the Committee determines
in its sole and absolute discretion. The Committee shall establish, in its sole and absolute discretion, the Performance Goals
for the applicable Performance Period for each Performance Share or Performance; Unit granted hereunder. Performance Goals for
different Participants and for different grants of Performance Shares and Performance Units need not be identical. Unless otherwise
provided in an Award Agreement, a holder of Performance Units or Performance Units is not entitled to the rights of a holder of
Common Stock.

 

    	10

    	 

    

 

(d)Determination
and Payment of Performance Units or Performance Shares Earned. Following the end of a Performance Period, the Committee
shall determine the extent to which Performance Shares or Performance Units have been earned on the basis of the Company’s
actual performance in relation to the established Performance Goals as set forth in the applicable Award Agreement and shall certify
these results in writing. Unless otherwise provided in an Award Agreement, the Committee shall determine in its sole and absolute
discretion whether payment with respect to the Performance Share or Performance Unit shall be made in cash, in shares of Common
Stock, or in a combination thereof.

 

(e)Termination
of Employment. Unless otherwise provided in an Award Agreement, if a Participant’s employment or other service
with the Company terminates for any reason, all of the Participant’s outstanding Performance Shares and Performance Units
shall be subject to the rules of this Section.

 

(i)Termination
for Reason Other Than Death or Disability. If a Participant’s employment or other service with the Company terminates
prior to the expiration of a Performance Period with respect to any Performance Units or Performance Shares held by such Participant
for any reason other than death or Disability, the outstanding Performance Units or Performance Shares held by such Participant
for which the Performance Period has not yet expired shall terminate upon such termination and the Participant shall have no further
rights pursuant to such Performance Units or Performance Shares.

 

(ii)Termination
of Employment for Death or Disability. If a Participant’s employment or other service with the Company terminates by
reason of the Participant’s death or Disability prior to the end of a Performance Period, the Participant, or the Participant’s
estate, devisee or heir at law (whichever is applicable) shall be entitled to a payment of the Participant’s outstanding
Performance Units and Performance Shares, pursuant to the terms of the Plan and the Participant’s Award Agreement; provided,
however, that the Participant shall be deemed to have earned only that proportion (to the nearest whole unit or share) of the Performance
Units or Performance Shares granted to the Participant under such Award as the number of full months of the Performance Period
which have elapsed since the first day of the Performance Period for which the Award was granted to the end of the month in which
the Participant’s termination of employment or other service, bears to the total number of months in the Performance Period,
subject to the attainment of the Performance Goals associated with the Award as certified by the Committee. The remaining Performance
Units or Performance Shares and any rights with respect thereto shall be canceled and forfeited.

 

    	11

    	 

    

 

10.OTHER
AWARDS

 

Awards of shares of
Common Stock, phantom stock and other Awards that are valued in whole or in part by reference to, or otherwise based on, Common
Stock, may also be made, from time to time, to Eligible Individuals as may be selected by the Committee. Such Common Stock may
be issued in satisfaction of Awards granted under any other plan sponsored by the Company or compensation payable to an Eligible
Individual. In addition, such Awards may be made alone or in addition to or in connection with any other Award granted hereunder.
The Committee may determine the terms and conditions of any such Award. Each such Award shall be evidenced by an Award Agreement
between the Eligible Individual and the Company which shall specify the number of shares of Common Stock subject to the Award,
any consideration therefore, any vesting or performance requirements and such other terms and conditions as the Committee shall
determine in its sole and absolute discretion.

 

11.CHANGE
IN CONTROL

 

Upon the occurrence
of a Change in Control, the Committee may, in its sole and absolute discretion, provide on a case by case basis (i) that all Awards
shall terminate, provided that Participants shall have the right, immediately prior to the occurrence of such Change in Control
and during such reasonable period as the Committee in its sole discretion shall determine and designate, to exercise any Award,
(ii) that all Awards shall terminate, provided that Participants shall be entitled to a cash payment equal to the Change in Control
Price with respect to shares subject to the vested portion of the Award net of the Exercise Price thereof, if applicable, (iii) that,
in connection with a liquidation or dissolution of Medytox, Awards, to the extent vested, shall convert into the right to receive
liquidation proceeds net of the Exercise Price (if applicable), (iv) for the acceleration of the vesting of Awards and (v) any
combination of the foregoing. In the event that the Committee does not terminate or convert an Award upon a Change in Control of
Medytox, then the Award shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring, or succeeding
corporation (or an affiliate thereof).

 

12.CHANGE
IN STATUS OF PARENT OR SUBSIDIARY

 

Unless otherwise provided
in an Award Agreement or otherwise determined by the Committee, in the event that an entity or business unit which was previously
a part of the Company is no longer a part of the Company, as determined by the Committee in its sole discretion, the Committee
may, in its sole and absolute discretion: (i) provide on a case by case basis that some or all outstanding Awards held by a Participant
employed by or performing service for such entity or business unit may become immediately exercisable or vested, without regard
to any limitation imposed pursuant to this Plan; (ii) provide on a case by case basis that some or all outstanding Awards held
by a Participant employed by or performing service for such entity or business unit may remain outstanding, may continue to vest,
and/or may remain exercisable for a period not exceeding one (1) year, subject to the terms of the Award Agreement and this Plan;
and/or (iii) treat the employment or other services of a Participant performing services for such entity or business unit as terminated
if such Participant is not employed by Medytox or any entity that is a part of the Company immediately after such event.

 

    	12

    	 

    

 

13.REQUIREMENTS
OF LAW

 

(a)Violations
of Law. The Company shall not be required to make any payments or sell or issue any shares of Common Stock under any
Award if the making of such payment or the sale or issuance of such shares would constitute a violation by the individual exercising
the Award, the Participant or the Company of any provisions of any law or regulation of any governmental authority, including without
limitation any provisions of the Sarbanes-Oxley Act, and any other federal or state securities laws or regulations. Any determination
in this connection by the Committee shall be final, binding, and conclusive. The Company shall not be obligated to take any affirmative
action in order to cause the exercise of an Award, the issuance of shares pursuant thereto or the grant of an Award to comply with
any law or regulation of any governmental authority.

 

(b)Registration.
At the time of any exercise or receipt of any Award, the Company may, if it shall determine it necessary or desirable for any
reason, require the Participant (or Participant’s heirs, legatees or legal representative, as the case may be), as a condition
to the exercise or grant thereof, to deliver to the Company a written representation of present intention to hold the shares for
their own account as an investment and not with a view to, or for sale in connection with, the distribution of such shares, except
in compliance with applicable federal and state securities laws with respect thereto. In the event such representation is required
to be delivered, an appropriate legend may be placed upon each certificate delivered to the Participant (or Participant’s
heirs, legatees or legal representative, as the case may be) upon the Participant’s exercise of part or all of the Award
or receipt of an Award and a stop transfer order may be placed with the transfer agent. Each Award shall also be subject to the
requirement that, if at any time the Company determines, in its discretion, that the listing, registration or qualification of
the shares subject to the Award upon any securities exchange or under any state or federal law, or the consent or approval of any
governmental regulatory body, is necessary or desirable as a condition of or in connection with, the issuance or purchase of the
shares thereunder, the Award may not be exercised in whole or in part and the restrictions on an Award may not be removed unless
such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not
acceptable to the Company in its sole discretion. The Participant shall provide the Company with any certificates, representations
and information that the Company requests and shall otherwise cooperate with the Company in obtaining any listing, registration,
qualification, consent or approval that the Company deems necessary or appropriate. The Company shall not be obligated to take
any affirmative action in order to cause the exercisability or vesting of an Award, to cause the exercise of an Award or the issuance
of shares pursuant thereto, or to cause the grant of Award to comply with any law or regulation of any governmental authority.

 

(c)Withholding.
The Committee may make such provisions and take such steps as it may deem necessary or appropriate for the withholding of any
taxes that the Company is required by any law or regulation of any governmental authority, whether federal, state or local, domestic
or foreign, to withhold in connection with the grant or exercise of an Award, or the removal of restrictions on an Award including,
but not limited to: (i) the withholding of delivery of shares of Common Stock until the holder reimburses the Company for the amount
the Company is required to withhold with respect to such taxes; (ii) the canceling of any number of shares of Common Stock issuable
in an amount sufficient to reimburse the Company for the amount it is required to so withhold; (iii) withholding the amount due
from any such person’s wages or compensation due to such person; or (iv) requiring the Participant to pay the Company cash
in the amount the Company is required to withhold with respect to such taxes.

 

(d)Governing Law.
The Plan shall be governed by, and construed and enforced in accordance with, the laws of the State of Nevada.

 

    	13

    	 

    

 

14.GENERAL
PROVISIONS

 

(a)Award Agreements.
All Awards granted pursuant to the Plan shall be evidenced by an Award Agreement. Each Award Agreement shall specify the terms
and conditions of the Award granted and shall contain any additional provisions as the Committee shall deem appropriate, in its
sole and absolute discretion (including, to the extent that the Committee deems appropriate, provisions relating to confidentiality,
non-competition, non-solicitation and similar matters). The terms of each Award Agreement need not be identical for Eligible Individuals
provided that each Award Agreement shall comply with the terms of the Plan.

 

(b)Purchase Price.
To the extent the purchase price of any Award granted hereunder is less than par value of a share of Common Stock and such
purchase price is not permitted by applicable law, the per share purchase price shall be deemed to be equal to the par value of
a share of Common Stock.

 

(c)Dividends and
Dividend Equivalents. Except as set forth in the Plan, an Award Agreement or provided by the Committee in its sole and
absolute discretion, a Participant shall not be entitled to receive, currently or on a deferred basis, cash or stock dividends,
Dividend Equivalents, or cash payments in amounts equivalent to cash or stock dividends on shares of Commons Stock covered by an
Award. The Committee in its absolute and sole discretion may credit a Participant’s Award with Dividend Equivalents with
respect to any Awards. To the extent that dividends and distributions relating to an Award are held in escrow by the Company, or
Dividend Equivalents are credited to an Award, a Participant shall not be entitled to any interest on any such amounts. The Committee
may not grant Dividend Equivalents to an Award subject to performance-based vesting to the extent that the grant of such Dividend
Equivalents would limit the Company’s deduction of the compensation payable under such Award for federal tax purposes pursuant
to Code Section 162(m).

 

(d)Deferral of
Awards. The Committee may from time to time establish procedures pursuant to which a Participant may elect to defer,
until a time or times later than the vesting of an Award, receipt of all or a portion of the shares of Common Stock or cash subject
to such Award and to receive Common Stock or cash at such later time or times, all on such terms and conditions as the Committee
shall determine. The Committee shall not permit the deferral of an Award unless counsel for Medytox determines that such action
will not result in adverse tax consequences to a Participant under Section 409A of the Code. If any such deferrals are permitted,
then notwithstanding anything to the contrary herein, a Participant who elects to defer receipt of Common Stock shall not have
any rights as a stockholder with respect to deferred shares of Common Stock unless and until shares of Common Stock are actually
delivered to the Participant with respect thereto, except to the extent otherwise determined by the Committee.

 

(e)Prospective
Employees. Notwithstanding anything to the contrary, any Award granted to a Prospective Employee shall not become vested
prior to the date the Prospective Employee first becomes an employee of the Company.

 

(f)Stockholder
Rights. Except as expressly provided in the Plan or an Award Agreement, a Participant shall not have any of the
rights of a stockholder with respect to Common Stock subject to the Awards prior to satisfaction of all conditions relating to
the issuance of such Common Stock, and no adjustment shall be made for dividends, distributions or other rights of any kind for
which the record date is prior to the date on which all such conditions have been satisfied.

 

    	14

    	 

    

 

(g)Transferability
of Awards. A Participant may not Transfer an Award other than by will or the laws of descent and distribution. Awards
may be exercised during the Participant’s lifetime only by the Participant. No Award shall be liable for or subject to the
debts, contracts, or liabilities of any Participant, nor shall any Award be subject to legal process or attachment for or against
such person. Any purported Transfer of an Award in contravention of the provisions of the Plan shall have no force or effect and
shall be null and void, and the purported transferee of such Award shall not acquire any rights with respect to such Award. Notwithstanding
anything to the contrary, the Committee may in its sole and absolute discretion permit the Transfer of an Award to a Participant’s
“family member” as such term is defined in the Form S-8 Registration Statement under the Securities Act of 1933, as
amended, under such terms and conditions as specified by the Committee. In such case, such Award shall be exercisable only by the
transferee approved of by the Committee. To the extent that the Committee permits the Transfer of an Incentive Stock Option to
a “family member”, so that such Option fails to continue to satisfy the requirements of an incentive stock option under
the Code such Option shall automatically be re-designated as a Non-Qualified Stock Option.

 

(h)Buyout and
Settlement Provisions. Except as prohibited in Section 6(d) of the Plan, the Committee may at any time on behalf of
Medytox offer to buy out any Awards previously granted based on such terms and conditions as the Committee shall determine which
shall be communicated to the Participants at the time such offer is made.

 

(i)Use of Proceeds.
The proceeds received by Medytox from the sale of Common Stock pursuant to Awards granted under the Plan shall constitute general
funds of Medytox.

 

(j)Modification
or Substitution of an Award. Subject to the terms and conditions of the Plan, the Committee may modify outstanding Awards,
provided that, except as expressly provided in the Plan, no modification of an Award shall adversely affect any rights or obligations
of the Participant under the applicable Award Agreement without the Participant’s consent. Nothing in the Plan shall limit
the right of the Company to pay compensation of any kind outside the terms of the Plan.

 

(k)Amendment and
Termination of Plan. The Board may, at any time and from time to time, amend, suspend or terminate the Plan as to any
shares of Common Stock as to which Awards have not been granted; provided, however, that the approval of the stockholders
of Medytox in accordance with applicable law and the Articles of Incorporation and Bylaws of Medytox shall be required for any
amendment: (i) that changes the class of individuals eligible to receive Awards under the Plan; (ii) that increases the maximum
number of shares of Common Stock in the aggregate that may be subject to Awards that are granted under the Plan (except as permitted
under Section 5 or Section 11 hereof); (iii) the approval of which is necessary to comply with federal or state law (including
without limitation Section 162(m) of the Code and Rule 16b-3 under the Exchange Act) or with the rules of any stock exchange or
automated quotation system on which the Common Stock may be listed or traded; or (iv) that proposed to eliminate a requirement
provided herein that the stockholders of Medytox must approve an action to be undertaken under the Plan. Except as expressly provided
in the Plan, no amendment, suspension or termination of the Plan shall, without the consent of the holder of an Award, alter or
impair rights or obligations under any Award theretofore granted under the Plan. Awards granted prior to the termination of the
Plan may extend beyond the date the Plan is terminated and shall continue subject to the terms of the Plan as in effect on the
date the Plan is terminated.

 

(l)Section 409A
and 162(m) of the Code. With respect to Awards subject to Section 409A or 162(m) of the Code, this Plan is intended
to comply with the requirements of such Sections, and the provisions hereof shall be interpreted in a manner that satisfies the
requirements of such Sections and the related regulations, and the Plan shall be operated accordingly. If any provision of this
Plan or any term or condition of any Award would otherwise frustrate or conflict with this intent, the provision, term or condition
will be interpreted and deemed amended so as to avoid this conflict.

 

(m)Notification
of 83(b) Election. If in connection with the grant of any Award, any Participant makes an election permitted under Code
Section 83(b), such Participant must notify Medytox in writing of such election within ten (10) days of filing such election with
the Internal Revenue Service.

 

    	15

    	 

    

 

(n)Disclaimer
of Rights. No provision in the Plan, any Award granted hereunder, or any Award Agreement entered into pursuant to the
Plan shall be construed to confer upon any individual the right to remain in the employ of or other service with the Company or
to interfere in any way with the right and authority of the Company either to increase or decrease the compensation of any individual,
including any holder of an Award, at any time, or to terminate any employment or other relationship between any individual and
the Company. The grant of an Award pursuant to the Plan shall not affect or limit in any way the right or power of the Company
to make adjustments, reclassifications, reorganizations or changes of its capital or business structure or to merge, consolidate,
dissolve or liquidate, or to sell or transfer all or any part of its business or assets.

 

(o)Unfunded Status
of Plan. The Plan is intended to constitute an “unfunded” plan for incentive and deferred compensation.
With respect to any payments as to which a Participant has a fixed and vested interest but which are not yet made to such Participant
by the Company, nothing contained herein shall give any such Participant any rights that are greater than those of a general creditor
of the Company.

 

(p)Nonexclusivity
of Plan. The adoption of the Plan shall not be construed as creating any limitations upon the right and authority of
the Board to adopt such other incentive compensation arrangements (which arrangements may be applicable either generally to a class
or classes of individuals or specifically to a particular individual or individuals) as the Board in its sole and absolute discretion
determines desirable.

 

(q)Other Benefits.
No Award payment under the Plan shall be deemed compensation for purposes of computing benefits under any retirement plan of
the Company or any agreement between a Participant and the Company, nor affect any benefits under any other benefit plan of the
Company now or subsequently in effect under which benefits are based upon a Participant’s level of compensation.

 

(r)Headings.
The section headings in the Plan are for convenience only; they form no part of this Agreement and shall not affect its interpretation.

 

(s)Pronouns.
The use of any gender in the Plan shall be deemed to include all genders, and the use of the singular shall be deemed to include
the plural and vice versa, wherever it appears appropriate from the context.

 

(t)Successors
and Assigns. The Plan shall be binding on all successors of the Company and all successors and permitted assigns of
a Participant, including, but not limited to, a Participant’s estate, devisee, or heir at law.

 

(u)Severability.
If any provision of the Plan or any Award Agreement shall be determined to be illegal or unenforceable by any court of law
in any jurisdiction, the remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms,
and all provisions shall remain enforceable in any other jurisdiction.

 

(v)Notices.
Any communication or notice required or permitted to be given under the Plan shall be in writing, and mailed by registered
or certified mail or delivered by hand, to Medytox, to its principal place of business, attention: Chief Financial Officer and
if to the holder of an Award, to the address as appearing on the records of the Company.

 

    	16

    	 

    

 

ANNEX A

 

DEFINITIONS

 

“Award”
means any Common Stock, Option, Performance Share, Performance Unit, Restricted Stock, Stock Appreciation Right or any other award
granted pursuant to the Plan.

 

“Award Agreement”
means a written agreement entered into by Medytox and a Participant setting forth the terms and conditions of the grant of an Award
to such Participant.

 

“Board”
means the board of directors of Medytox.

 

“Cause”
means, with respect to a termination of employment or other service with the Company, a termination of employment or other service
due to a Participant’s dishonesty, fraud, insubordination, willful misconduct, refusal to perform services (for any reason
other than illness or incapacity) or materially unsatisfactory performance of the Participant’s duties for the Company; provided,
however, that if the Participant and the Company have entered into an employment agreement or consulting agreement which defines
the term Cause, the term Cause shall be defined in accordance with such agreement with respect to any Award granted to the Participant
on or after the effective date of the respective employment or consulting agreement. The Committee shall determine in its sole
and absolute discretion whether Cause exists for purposes of the Plan.

 

“Change in Control”
means:  (i) any Person (other than Medytox, any trustee or other fiduciary holding securities under any employee benefit plan
of Medytox, or any company owned, directly or indirectly, by stockholders of Medytox in substantially the same proportions as their
ownership of Medytox Common Stock) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of securities of Medytox representing more than fifty percent (50%) or more of the value of Medytox’s
then outstanding securities (the “Majority Owner”); provided, however, that no Change in Control shall occur under
this paragraph (i) unless a person who was not a Majority Owner at some time after the Effective Date becomes a Majority Owner
after the Effective Date; (ii) a merger, consolidation, reorganization, or other business combination of Medytox with any other
entity, other than a merger or consolidation which would result in the securities of Medytox outstanding immediately prior thereto
continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity)
more than fifty percent (50%) by value of the securities of Medytox or such surviving entity outstanding immediately after such
merger or consolidation; or (iii)the consummation of the sale or disposition by Medytox of all or substantially all of its
assets other than (x) the sale or disposition of all or substantially all of the assets of the Company to a Person or Persons who
beneficially own, directly or indirectly, at least fifty percent (50%) or more of the securities of Medytox by value at the time
of the sale or (y) pursuant to a spin-off type transaction, directly or indirectly, of such assets to the stockholders of the Medytox.

 

However, to the extent
that Section 409A of the Code would cause an adverse tax consequence to a Participant using the above definition, the term “Change
in Control” shall have the meaning ascribed to the phrase “Change in the Ownership or Effective Control of a Corporation
or in the Ownership of a Substantial Portion of the Assets of a Corporation” under Treasury Department Regulation 1.409A-3(i)(5),
as revised from time to time in either subsequent regulations or other guidance, and in the event that such regulations are withdrawn
or such phrase (or a substantially similar phrase) ceases to be defined, as determined by the Committee.

 

    	A-1

    	 

    

 

“Change in Control
Price” means the price per share of Common Stock paid in any transaction related to a Change in Control of Medytox.

 

“Code”
means the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.

 

“Committee”
means a committee or sub-committee of the Board consisting of two or more members of the Board, none of whom shall be an officer
or other salaried employee of the Company, and each of whom shall qualify in all respects as a “non-employee director”
as defined in Rule 16b-3 under the Exchange Act, and as an “outside director” for purposes of Code Section 162(m).
If no Committee exists, the functions of the Committee will be exercised by the Board; provided, however, that a Committee
shall be created prior to the grant of Awards to a Covered Employee and that grants of Awards to a Covered Employee shall be made
only by such Committee. Notwithstanding the foregoing, with respect to the grant of Awards to non-employee directors, the Committee
shall be the Board.

 

“Common Stock”
means the common stock, par value $0.0001 per share, of Medytox or any other security into which such common stock shall be changed
as contemplated by the adjustment provisions of Section 5 of the Plan.

 

“Company”
means Medytox, the subsidiaries of Medytox and all other entities whose financial statements are required to be consolidated with
the financial statements of Medytox pursuant to United States generally accepted accounting principles, and any other entity determined
to be an affiliate of Medytox as determined by the Committee in its sole and absolute discretion.

 

“Covered Employee”
means “covered employee” as defined in Code Section 162(m)(3).

 

“Covered Individual”
means any current or former member of the Committee, any current or former officer or director of the Company, or, if so determined
by the Committee in its sole discretion, any individual designated pursuant to Section 4(c).

 

“Disability”
means a “permanent and total disability” within the meaning of Code Section 22(e)(3); provided, however, that
if a Participant and the Company have entered into an employment or consulting agreement which defines the term Disability for
purposes of such agreement, Disability shall be defined pursuant to the definition in such agreement with respect to any Award
granted to the Participant on or after the effective date of the respective employment or consulting agreement. The Committee shall
determine in its sole and absolute discretion whether a Disability exists for purposes of the Plan.

 

    	A-2

    	 

    

 

“Dividend Equivalents”
means an amount equal to the cash dividends paid by the Company upon one share of Common Stock subject to an Award granted to a
Participant under the Plan.

 

“Eligible Individual”
means any employee, consultant, officer, director (employee or non-employee director) or independent contractor of the Company
and any Prospective Employee to whom Awards are granted in connection with an offer of future employment with the Company.

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended.

 

“Exercise Price”
means the purchase price per share of each share of Common Stock subject to an Award.

 

“Fair Market
Value” means, unless otherwise required by the Code, as of any date, the last sales price reported for the Common Stock on
the day immediately prior to such date (i) as reported by the national securities exchange in the United States on which it is
then traded, or (ii) if not traded on any such national securities exchange, as quoted on an automated quotation system sponsored
by the Financial Industry Regulatory Authority, Inc., or if the Common Stock shall not have been reported or quoted on such date,
on the first day prior thereto on which the Common Stock was reported or quoted; provided, however, that the Committee may
modify the definition of Fair Market Value to reflect any changes in the trading practices of any exchange or automated system
sponsored by the Financial Industry Regulatory Authority, Inc. on which the Common Stock is listed or traded. If the Common Stock
is not readily traded on a national securities exchange or any system sponsored by the Financial Industry Regulatory Authority,
Inc., the Fair Market Value shall be determined in good faith by the Committee.

 

“Grant Date”
means, unless otherwise provided by applicable law, the date on which the Committee approves the grant of an Award or such later
date as is specified by the Committee and set forth in the applicable Award Agreement.

 

“Incentive Stock
Option” means an “incentive stock option” within the meaning of Code Section 422.

 

“Medytox”
means Medytox Solutions, Inc., a Nevada corporation.

 

“Non-Qualified
Stock Option” means an Option which is not an Incentive Stock Option.

 

“Option”
means an option to purchase Common Stock granted pursuant to Sections 6 of the Plan.

 

“Participant”
means any Eligible Individual who holds an Award under the Plan and any of such individual’s successors or permitted assigns.

 

“Performance
Goals” means the specified performance goals which have been established by the Committee in connection with an Award.

 

    	A-3

    	 

    

 

“Performance
Period” means the period during which Performance Goals must be achieved in connection with an Award granted under the Plan.

 

“Performance
Share” means a right to receive a fixed number of shares of Common Stock, or the cash equivalent, which is contingent on
the achievement of certain Performance Goals during a Performance Period.

 

“Performance
Unit” means a right to receive a designated dollar value, or shares of Common Stock of the equivalent value, which is contingent
on the achievement of Performance Goals during a Performance Period.

 

“Person”
shall mean any person, corporation, partnership, limited liability company, joint venture or other entity or any group (as such
term is defined for purposes of Section 13(d) of the Exchange Act), other than a Parent or subsidiary of the Company.

 

“Plan”
means this Medytox Solutions, Inc. 2013 Incentive Compensation Plan.

 

“Prospective
Employee” means any individual who has committed to become an employee or independent contractor of the Company within sixty
(60) days from the date an Award is granted to such individual.

 

“Restricted Stock”
means Common Stock subject to certain restrictions, as determined by the Committee, and granted pursuant to Section 8 hereunder.

 

“Section 424
Employee” means an employee of Medytox or any “subsidiary corporation” or “parent corporation” as
such terms are defined in and in accordance with Code Section 424. The term “Section 424 Employee” also includes employees
of a corporation issuing or assuming any Options in a transaction to which Code Section 424(a) applies.

 

“Stock Appreciation
Right” means the right to receive all or some portion of the increase in value of a fixed number of shares of Common Stock
granted pursuant to Section 7 hereunder.

 

“Transfer”
means, as a noun, any direct or indirect, voluntary or involuntary, exchange, sale, bequeath, pledge, mortgage, hypothecation,
encumbrance, distribution, transfer, gift, assignment or other disposition or attempted disposition of, and, as a verb, directly
or indirectly, voluntarily or involuntarily, to exchange, sell, bequeath, pledge, mortgage, hypothecate, encumber, distribute,
transfer, give, assign or in any other manner whatsoever dispose or attempt to dispose of.

 

    	A-4Exhibit 10.16

 

 

August 15, 2013

 

Margo Smith

VIA ELECTRONIC DELIVERY

 

Dear Margo:

 

Marketo, Inc. (the “Company”) is pleased to offer you employment on the following terms:

 

1.              Position.  Your title will be SVP, General Counsel, and Secretary, and you will report to Phil Fernandez.  This is a full-time, exempt position.  While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company.  By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.

 

Your work location will be the Company’s offices in San Mateo, California.

 

2.              Cash Compensation.  The Company will pay you a starting salary at the rate of $275,000 per year, payable in accordance with the Company’s standard payroll schedule.  This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time.

 

In addition, you will be eligible for an MBO bonus plan, details of which will be established.  Your total on target compensation under the MBO bonus plan for the first calendar year of your employment will be $100,000,  annualized and prorated from your hire date.

 

You will also receive a one-time sign-on bonus of $25,000,  one-half of which will be paid to you after 30 days of employment, and the other half which will be paid to you after 120 days of employment.  Should you voluntarily terminate from the Company within the first year after your start date, the sign-on bonus must be paid back in full to the Company.

 

3.              Employee Benefits.  As a regular employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits.  These benefits are described in the Company’s employee benefit summary.  In addition, you will be entitled to paid vacation in accordance with the Company’s vacation policy, as in effect from time to time.

 

4.              Equity.

 

Stock Options.  Subject to the approval of the Company’s Board of Directors or its Compensation or Equity Management Committee and in accordance with Marketo’s equity award grant policy, you will be granted an option to purchase 21,500 shares of the Company’s Common Stock.  The exercise price per share will be determined by the Board of Directors or its Compensation or Equity Management Committee when the option is granted.  The option will be subject to the terms and conditions applicable to options granted under the Company’s 2013 Stock Plan (the “Plan”), as described in the Plan and the applicable stock option agreement.  You will vest in 25% of the option shares after 12 months of continuous service, and the balance will vest in equal monthly installments over the next 36 months of continuous service, as described in the applicable stock option agreement.

 

Restricted Stock Unit Award.  Subject to the approval of the Company’s Board of Directors or its Compensation or Equity Management Committee and in accordance with Marketo’s equity award grant

 

Marketo, Inc.  |  901 Mariners Island Blvd., Suite 200, San Mateo, CA 94404  |  +1 650 376 2300

 

 

policy, you will be granted 21,500 restricted stock units under the Plan. The RSUs will be subject to the terms and conditions of the Plan as described in the Plan and the applicable restricted stock unit agreement to be signed by you and the Company, which will be provided to you as soon as practicable after the grant date and which you will be required to sign.  You agree to electronic delivery and acceptance of the applicable equity documents.  The RSUs will vest and become non-forfeitable (assuming your continued employment with the Marketo group on each vesting date) as follows: 25% each on the first, second, third and fourth anniversary of the grant date.

 

5.              Change in Control. In addition, you will be subject to our Tier II Change in Control Policy, which includes 12 months of salary and COBRA reimbursement, 100% acceleration of unvested equity, as well as other benefits, which will be detailed in a separate agreement. Along with Marketo’s CEO and CFO, you will be exempt from certain “Good Reason” restrictions as per the Agreement.

 

6.              Proprietary Information and Inventions Agreement.  Like all Company employees, you will be required, as a condition of your employment with the Company, to sign the Company’s standard Proprietary Information and Inventions Agreement a copy of which is attached hereto.

 

7.              Global Code of Conduct.  A copy of our Global Code of Conduct, which you are also subject to, is attached. Please familiarize yourself with this document prior to your start date.

 

8.              Employment Relationship.  Employment with the Company is for no specific period of time.  Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause.  Any contrary representations that may have been made to you are superseded by this letter agreement.  This is the full and complete agreement between you and the Company on this term.  Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company.

 

9.              Taxes.  All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.  You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation.

 

10.       Interpretation, Amendment and Enforcement.  This letter agreement and Exhibit A constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.  This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company.  The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by California law, excluding laws relating to conflicts or choice of law.  You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in San Mateo County in connection with any Dispute or any claim related to any Dispute.

 

* * * * *

 

We hope that you will accept our offer to join the Company.  You may indicate your agreement with these terms and accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Proprietary Information and Inventions Agreement and returning them to me.  This offer, if not accepted, will expire at the close of business on August 19, 2013.  As required by law, your employment with the Company is contingent upon your providing legal proof of your identity and authorization to work in the United States.  Your offer is further conditioned upon acceptable reference and background checks.  Your employment is also contingent upon your starting work with the Company no later than September 16, 2013.

 

 

Margo, we’re very excited to have you join our team at Marketo.  If you have any questions, please call me at 650 387 8459.

 

	
 
    	
 
    	
Very truly yours,
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
/s/ Phillip M. Fernandez
    
	
 
    	
 
    	
Phillip M. Fernandez
   President & CEO
   Marketo, Inc.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
I have read and accept this employment offer:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Margo Smith
    	
 
    	
 
    
	
Signature of Margo Smith
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Dated:
    	
8/16/2013
    	
 
    	
 
    
				

 

Attachments

 

Exhibit A: Proprietary Information and Inventions Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]